At the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), data from a Phase 1, randomized, double-blind, placebo-controlled, single-center study of IV radezolid administered once daily for up to 14 days was presented. The IV formulation of radezolid was well tolerated in healthy subjects and approximately dose proportional in single or multiple daily doses up to 14 days. The ability of radezolid to be administered either orally or through IV greatly increases its potential utility as a treatment option for drug-resistant and gram-positive bacteria.

Radezolid is a next-generation oxazolidinone designed to be a potent antibiotic with intravenous (IV) and oral formulations and a safety profile permitting long-term treatment of resistant infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Radezolid has completed two Phase 2 clinical trials with an oral formulation in uncomplicated skin and skin structure infections (uSSSI) and in community acquired bacterial pneumonia (CABP). A Phase 1 study with an IV formulation was recently completed in healthy subjects.

For more information visit